CNS activity of Pokeweed Anti-viral Protein (PAP) in mice infected with Lymphocytic Choriomeningitis Virus (LCMV)

BMC Infectious Diseases

Volumn 5, Issue , 2005, Pages

  Uckun, Fatih M ^a   Rustamova, Larisa ^b   Vassilev, Alexei O ^a   Tibbles, Heather E ^a   Petkevich, Alexander S ^b  

^a Drug Discovery Program   (United States)

^b Research Institute for Epidemiology & Microbiology RIEM   (Belarus)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DRUG VEHICLE; POKEWEED ANTIVIRUS PROTEIN; GLYCOSIDASE; PROTEIN SYNTHESIS INHIBITOR; RIBOSOME INACTIVATING PROTEIN 1; VEGETABLE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MOUSE; NONHUMAN; SURVIVAL TIME; SYMPTOMATOLOGY; VIRUS MENINGITIS; ANIMAL; BRAIN; CBA MOUSE; DISEASE MODEL; DRUG EFFECT; LYMPHOCYTIC CHORIOMENINGITIS; METABOLISM; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; BRAIN; DISEASE MODELS, ANIMAL; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MICE; MICE, INBRED CBA; N-GLYCOSYL HYDROLASES; PLANT PROTEINS; PROTEIN SYNTHESIS INHIBITORS; RIBOSOME INACTIVATING PROTEINS, TYPE 1;

EID: 25444501020     PISSN: 14712334     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-5-9     Document Type: Article

References (56)

1. Irvin JD, Uckun FM: Pokeweed antiviral protein: ribosome inactivation and therapeutic applications. Pharmacol Ther 1992, 55(3):279-302.
2. D'Cruz OJ, Waurzyniakt B, Uckun FM: A 13-week subchronic intravaginal toxicity study of pokeweed antiviral protein in mice. Phytomedicine 2004, 11(4):342-351.
3. Parikh BA, Turner NE: Antiviral activity of ribosome inactivating proteins in medicine. Mini Rev Med Chem 2004, 4(5):523-543.
4. Rajamohan F, Ozer Z, Mao C, Uckun FM: Active center cleft residues of pokeweed antiviral protein mediate its high-affinity binding to the ribosomal protein L3. Biochemistry 2001, 40(31):9104-9114.
5. Kurinov IV, Uckun FM: High resolution X-ray structure of potent anti-HIV pokeweed antiviral protein-III. Biochem Pharmacol 2003, 65(10):1709-1717.
6. Uckun FM, Rajamohan F, Pendergrass S, Ozer Z, Waurzyniak B, Mao C: Structure-based design and engineering of a nontoxic recombinant pokeweed antiviral protein with potent anti-human immunodeficiency virus activity. Antimicrob Agents Chemother 2003, 47(3):1052-1061.
7. Rajamohan F, Mao C, Uckun FM: Binding interactions between the active center cleft of recombinant pokeweed antiviral protein and the alpha-sarcin/ricin stem loop of ribosomal RNA. J Biol Chem 2001, 276(26):24075-24081.
8. D'Cruz OJ, Uckun FM: Pokeweed antiviral protein: a potential nonspermicidal prophylactic antiviral agent. Fertil Steril 2001, 75(1):106-114.
9. Kurinov IV, Mao C, Irvin JD, Uckun FM: X-ray crystallographic analysis of pokeweed antiviral protein-II after reductive methylation of lysine residues. Biochem Biophys Res Commun 2000, 275(2):549-552.
10. Rajamohan F, Doumbia SO, Engstrom CR, Pendergras SL, Maher DL, Uckun FM: Expression of biologically active recombinant pokeweed antiviral protein in methylotrophic yeast Pichia pastoris. Protein Expr Purif 2000, 18(2):193-201.
11. Rajamohan F, Pugmire MJ, Kurinov IV, Uckun FM: Modeling and alanine scanning mutagenesis studies of recombinant pokeweed antiviral protein. J Biol Chem 2000, 275(5):3382-3390.
12. Kurinov IV, Rajamohan F, Venkatachalam TK, Uckun FM: X-ray crystallographic analysis of the structural basis for the interaction of pokeweed antiviral protein with guanine residues of ribosomal RNA. Protein Sci 1999, 8(11):2399-2405.
13. Uckun FM, Bellomy K, O'Neill K, Messinger Y, Johnson T, Chen CL: Toxicity, biological activity, and pharmacokinetics of TXU (anti-CD7)-pokeweed antiviral protein in chimpanzees and adult patients infected with human immunodeficiency virus. J Pharmacol Exp Ther 1999, 291(3):1301-1307.
14. Kurinov IV, Myers DE, Irvin JD, Uckun FM: X-ray crystallographic analysis of the structural basis for the interactions of pokeweed antiviral protein with its active site inhibitor and ribosomal RNA substrate analogs. Protein Sci 1999, 8(9):1765-1772.
15. Rajamohan F, Kurinov IV, Venkatachalam TK, Uckun FM: Deguanylation of human immunodeficiency virus (HIV-1) RNA by recombinant pokeweed antiviral protein. Biochem Biophys Res Commun 1999, 263(2):419-424.
16. Rajamohan F, Engstrom CR, Denton TJ, Engen LA, Kourinov I, Uckun FM: High-level expression and purification of biologically active recombinant pokeweed antiviral protein. Protein Expr Purif 1999, 16(2):359-368.
17. Rajamohan F, Venkatachalam TK, Irvin JD, Uckun FM: Pokeweed antiviral protein isoforms PAP-I, PAP-II, and PAP-III depurinate RNA of human immunodeficiency virus (HIV)-1. Biochem Biophys Res Commun 1999, 260(2):453-458.
18. Waurzyniak B, Schneider EA, Turner N, Yanishevski Y, Gunther R, Chelstrom LM, Wendorf H, Myers DE, Irvin JD, Messinger Y, Ek O, Zeren T, Langlie MC, Evans WE, Uckun FM: In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin. Clin Cancer Res 1997, 3(6):881-890.
19. Uckun FM, Yanishevski Y, Turner N, Waurzyniak B, Messinger Y, Chelstrom LM, Lisowski EA, Ek O, Zeren T, Wendorf H, Langlie MC, Irvin JD, Myers DE, Fuller GB, Evans W, Gunther R: Pharmacokinetic features, immunogenicity, and toxicity of B43(anti-CD19)-pokeweed antiviral protein immunotoxin in cynomolgus monkeys. Clin Cancer Res 1997, 3(3):325-337.
20. Ek O, Waurzyniak B, Myers DE, Uckun FM: Antitumor activity of TP3(anti- p80)-pokeweed antiviral protein immunotoxin in hamster cheek pouch and severe combined immunodeficient mouse xenograft models of human osteosarcoma. Clin Cancer Res 1998, 4(7):1641-1647.
21. Uckun FM, Chelstrom LM, Tuel-Ahlgren L, Dibirdik I, Irvin JD, Langlie MC, Myers DE: TXU (anti-CD7)-pokeweed antiviral protein as a potent inhibitor of human immunodeficiency virus. Antimicrob Agents Chemother 1998, 42(2):383-388.
22. Myers DE, Jun X, Clementson D, Donelson R, Sicheneder A, Hoffman N, Bell K, Sarquis M, Langlie MC, Turner N, Uckun FM: Large scale manufacturing of TXU(anti-CD7)-pokeweed antiviral protein (PAP) immunoconjugate for clinical trials. Leuk Lymphoma 1997, 27(3-4):275-302.
23. Zoubenko O, Uckun F, Hur Y, Chet I, Turner N: Plant resistance to fungal infection induced by nontoxic pokeweed antiviral protein mutants. Nat Biotechnol 1997, 15(10):992-996.
24. Gunther R, Chelstrom LM, Wendorf HR, Schneider EA, Covalciuc K, Johnson B, Clementson D, Irvin JD, Myers DE, Uckun FM: Toxicity profile of the investigational new biotherapeutic agent, B43 (anti-CD19)-pokeweed antiviral protein immunotoxin. Leuk Lymphoma 1996, 22(1-2):61-70. follow 186, color plate II-V
25. Waddick KG, Myers DE, Gunther R, Chelstrom LM, Chandan-Langlie M, Irvin JD, Tumer N, Uckun FM: In vitro and in vivo antileukemic activity of B43-pokeweed antiviral protein against radiation-resistant human B-cell precursor leukemia cells. Blood 1995, 86(11):4228-4233.
26. Hur Y, Hwang DJ, Zoubenko O, Coetzer C, Uckun FM, Tumer NE: Isolation and characterization of pokeweed antiviral protein mutations in Saccharomyces cerevisiae: identification of residues important for toxicity. Proc Natl Acad Sci U S A 1995, 92(18):8448-8452.
27. Myers DE, Yanishevski Y, Masson E, Irvin JD, Evans WE, Uckun FM: Favorable pharmacodynamic features and superior anti-leukemic activity of B43 (anti-CD 19) immunotoxins containing two pokeweed antiviral protein molecules covalently linked to each monoclonal antibody molecule. Leuk Lymphoma 1995, 18(1-2):93-102.
28. Gunther R, Chelstrom LM, Tuel-Ahlgren L, Simon J, Myers DE, Uckun FM: Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin. Blood 1995, 85(9):2537-2545.
29. Anderson PM, Meyers DE, Hasz DE, Covalcuic K, Saltzman D, Khanna C, Uckun FM: In vitro and in vivo cytotoxicity of an anti-osteosarcoma immunotoxin containing pokeweed antiviral protein. Cancer Res 1995, 55(6):1321-1327.
30. Erice A, Balfour HH Jr, Myers DE, Leske VL, Sannerud KJ, Kuebelbeck V, Irvin JD, Uckun FM: Anti-human immunodeficiency virus type 1 activity of an anti-CD4 immunoconjugate containing pokeweed antiviral protein. Antimicrob Agents Chemother 1993, 37(4):835-838.
31. Uckun FM, Myers DE, Irvin JD, Kuebelbeck VM, Finnegan D, Chelstrom LM, Houston LL: Effects of the intermolecular toxinmonoclonal antibody linkage on the in vivo stability, immunogenicity and anti-leukemic activity of B43 (anti-CD19) pokeweed antiviral protein immunotoxin. Leuk Lymphoma 1993, 9(6):459-476.
32. Gunther R, Chelstrom LM, Finnegan D, Tuel-Ahlgren L, Irvin JD, Myers DE, Uckun FM: In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency. Leukemia 1993, 7(2):298-309.
33. Jansen B, Kersey JH, Jaszcz WB, Gunther R, Nguyen DP, Chelstrom LM, Tuel-Ahlgren L, Uckun FM: Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide. Leukemia 1993, 7(2):290-297.
34. Uckun FM, Haissig S, Ledbetter JA, Fidler P, Myers DE, Kuebelbeck V, Weisdorf D, Gajl-Peczalska K, Kersey JH, Ramsay NK: Developmental hierarchy during early human B-cell ontogeny after autologous bone marrow transplantation using autografts depleted of CD19+ B-cell precursors by an anti-CD 19 pan-B-cell immunotoxin containing pokeweed antiviral protein. Blood 1992, 79(12):3369-3379.
35. Uckun FM, Chelstrom LM, Finnegan D, Tuel-Ahlgren L, Manivel C, Irvin JD, Myers DE, Gunther R: Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide. Blood 1992, 79(12):3116-3129.
36. Uckun FM, Chelstrom LM, Irvin JD, Finnegan D, Gunther R, Young J, Kuebelbeck V, Myers DE, Houston LL: In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against BCL-1 murine B-cell leukemia. Blood 1992, 79(10):2649-2661.
37. Uckun FM, Manivel C, Arthur D, Chelstrom LM, Finnegan D, Tuel-Ahlgren L, Irvin JD, Myers DE, Gunther R: In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency. Blood 1992, 79(9):2201-2214.
38. Myers DE, Irvin JD, Smith RS, Kuebelbeck VM, Uckun FM: Production of a pokeweed antiviral protein (PAP)-containing immunotoxin, B43-PAP, directed against the CD19 human B lineage lymphoid differentiation antigen in highly purified form for human clinical trials. J Immunol Methods 1991, 136(2):221-237.
39. Zarling JM, Moran PA, Haffar O, Diegel M, Myers DE, Kuelbeck V, Ledbetter JA, Uckun FM: Inhibition of HIV-1 replication in seropositive patients' CD4+ T-cells by pokeweed antiviral protein-monoclonal antibody conjugates. Int J Immunopharmacol 1991, 13(Suppl 1):63-68.
40. Uckun FM, Gajl-Peczalska KJ, Kersey JH, Houston LL, Vallera DA: Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia. J Exp Med 1986, 163(2):347-368.
41. Ramakrishnan S, Uckun FM, Houston LL: Anti-T cell immunotoxins containing pokeweed anti-viral protein: potential purging agents for human autologous bone marrow transplantation. J Immunol 1985, 135(5):3616-3622.
42. Uckun FM, Ramakrishnan S, Houston LL: Ex vivo elimination of neoplastic T-cells from human marrow using an anti-Mr 41,000 protein immunotoxin: potentiation by ASTA Z 7557. Blut 1985, 50(1):19-23.
43. Kappes DJ, Lawrence DM, Vaughn MM, Dave VP, Belman AR, Rall GF: Protection of CD3 delta knockout mice from lymphocytic choriomeningitis virus-induced immunopathology: implications for viral neuroinvasion. Virology 2000, 269(2):248-256.
44. Asensio VC, Kincaid C, Campbell IL: Chemokines and the inflammatory response to viral infection in the central nervous system with a focus on lymphocytic choriomeningitis virus. J Neurovirol 1999, 5(1):65-75.
45. Cao W, Henry MD, Borrow P, Yamada H, Elder JH, Ravkov EV, Nichol ST, Compans RW, Campbell KP, Oldstone MB: Identification of alpha dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science 1998, 282(5396):2079-2081.
46. Smelt SC, Borrow P, Kunz S, Cao W, Tishon A, Lewicki H, Campbell KP, Oldstone MB: Differences in affinity of binding of lymphocytic choriomeningitis virus strains to the cellular receptor alpha-dystroglycan correlate with viral tropism and disease kinetics. J Virol 2001, 75(1):448-457.
47. Barton LL, Hyndman NJ: Lymphocytic choriomeningitis virus: reemerging central nervous system pathogen. Pediatrics 2000, 105(3):E35.
48. Gisslen M, Hagberg L: Antiretroviral treatment of central nervous system HIV-1 infection: a review. HIV Med 2001, 2(2):97-104.
49. Mamidi A, DeSimone JA, Pomerantz RJ: Central nervous system infections in individuals with HIV-1 infection. J Neurovirol 2002, 8(3):158-167.
50. McCoig C, Castrejon MM, Castano E, De Suman O, Baez C, Redondo W, McClernon D, Danehower S, Lanier ER, Richardson C, Keller A, Hetherington S, Saez-Llorens X, Ramilo O: Effect of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV resistance, and clinical manifestations of encephalopathy. J Pediatr 2002, 141(1):36-44.
51. Center for Disease Control (CDC) Special Pathogen Branch [http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/lcmv.htm]
52. Hudak KA, Bauman JD, Turner NE: Pokeweed antiviral protein binds to the cap structure of eukaryotic mRNA and depurinates the mRNA downstream of the cap. Rna 2002, 8(9):1148-1159.
53. Chen JP, Cosgriff TM: Hemorrhagic fever virus-induced changes in hemostasis and vascular biology. Blood Coagul Fibrinolysis 2000, 11(5):461-483.
54. Peterson AT, Bauer JT, Mills JN: Ecologic and geographic distribution of filovirus disease. Emerg Infect Dis 2004, 10(1):40-47.
55. Feldmann H, Jones S, Klenk HD, Schnittler HJ: Ebola virus: from discovery to vaccine. Nat Rev Immunol 2003, 3(8):677-685.
56. Sullivan N, Yang ZY, Nabel GJ: Ebola virus pathogenesis: implications for vaccines and therapies. J Virol 2003, 77(18):9733-9737.